Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $47.2300 (2.14%) ($47.2300 - $47.2300) on Fri. Feb. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.38% (three month average) | RSI | 48 | Latest Price | $47.2300(2.14%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.2% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(64%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.19% in a week (0% probabilities). VIXM(-42%) VXX(-36%) UUP(-19%) UNG(-3%) TBT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.19% (StdDev 6.38%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $48.83 | 5 Day Moving Average | $46.84(0.83%) | 10 Day Moving Average | $48.88(-3.38%) | 20 Day Moving Average | $48.83(-3.28%) | To recent high | -13.7% | To recent low | 73.8% | Market Cap | $5.982b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |